Explain the graph only..in the given picture
Graph Explanation: Hemoglobin Development Over Time
This graph shows % of total globin chain synthesis on the Y-axis plotted against time on the X-axis, which is divided into three phases:
X-Axis (Time Phases)
- Fetal weeks 6–36 (gestational weeks)
- Postnatal months 6–36
- Adult (beyond that)
Top Band — Site of Erythropoiesis
Before the curves, a color-coded band shows where blood is being made at each time point:
| Site | Period |
|---|---|
| 🟡 Yolk sac | Weeks 3–8 |
| 🟤 Liver | Weeks 6 – birth |
| 🔴 Spleen | Weeks 10–28 |
| 🟢 Bone marrow | Week 18 → adult (dominant after birth) |
The Globin Chain Curves
🟡 Embryonic Globins — ζ (zeta) and ε (epsilon)
- Present only in the first 6–8 weeks of fetal life
- Spike sharply early, then rapidly disappear — these are the first globins made in the yolk sac
🔴 α (Alpha) chain
- Rises early (~week 6) and stays constantly ~50% throughout fetal life, birth, and into adulthood
- Alpha is always present because all hemoglobin types (HbF, HbA, HbA₂) use alpha chains
🟣 γ (Gamma) chain — Fetal Hb (HbF = α₂γ₂)
- Rises to ~40–45% in fetal life
- Remains dominant until around birth (week 36)
- Then sharply declines after birth, approaching near zero by ~6–12 postnatal months
- This curve represents HbF, which gives the fetus higher O₂ affinity
🟢 β (Beta) chain — Adult Hb (HbA₁ = α₂β₂)
- Very low during fetal life
- Rises sharply after birth, becoming the dominant chain by ~6 postnatal months
- Stabilizes at ~50% in adults — this represents HbA₁, the major adult hemoglobin
🔵 δ (Delta) chain — HbA₂ (α₂δ₂)
- Appears after birth in very small amounts
- Stays at a low, flat level (~2–3%) throughout adult life
- Represents HbA₂, a minor adult hemoglobin
Key Takeaway: The Switch at Birth
The most dramatic event on the graph is the γ → β switch around birth:
- Before birth: γ chains dominate → HbF (high O₂ affinity, ideal for pulling O₂ from the mother)
- After birth: β chains take over → HbA (standard adult hemoglobin)
This switch is clinically important — conditions like sickle cell disease and β-thalassemia only become symptomatic after birth once HbF levels fall and the defective β chains take over.
What causes the hemoglobin switch at birth?
Reading File
Finding Sources
Searching PubMed
fetal hemoglobin switch gamma beta globin mechanism
Searching the Web
mechanism hemoglobin switch birth gamma to beta globin BCL11A KLF1
Finding Sources
Finding Sources
Reading File
Finding Sources
Here is a comprehensive explanation of what causes the hemoglobin switch at birth:
The Hemoglobin Switch at Birth: γ → β
The switch from fetal hemoglobin (HbF, α₂γ₂) to adult hemoglobin (HbA, α₂β₂) is one of the most well-studied gene regulation events in human biology. It involves multiple layers of control — anatomical, transcriptional, and epigenetic.
1. The Trigger: Change in Site of Erythropoiesis
The most fundamental driver is the shift in where blood cells are made:
| Phase | Site | Globin Produced |
|---|---|---|
| Embryonic (weeks 3–8) | Yolk sac | ζ, ε (embryonic) |
| Fetal | Liver + Spleen | γ (HbF dominant) |
| Perinatal/Postnatal | Bone marrow | β (HbA dominant) |
When hematopoiesis transitions to the bone marrow around birth, the erythroid progenitor environment changes, which is closely tied to γ-globin silencing and β-globin activation.
2. The Master Molecular Switch: BCL11A
The single most important molecular mediator of the switch is the transcription factor BCL11A:
- BCL11A is a repressor — it directly silences the γ-globin genes (HBG1 and HBG2) in adult erythroid cells
- Its expression rises dramatically around the perinatal period in bone marrow–derived erythroid progenitors
- When BCL11A binds the β-globin locus, it occupies a critical 3.5 kb region near the γ-globin gene, blocking its transcription
- Mutations or deletions that disrupt BCL11A binding sites → γ-globin stays on → Hereditary Persistence of Fetal Hemoglobin (HPFH)
This is why BCL11A is now a therapeutic target: gene therapy for sickle cell disease works by knocking out the BCL11A erythroid enhancer to reactivate HbF production (Casgevy/exa-cel, approved 2023).
3. The "Double Whammy" Model: KLF1
KLF1 (Krüppel-like Factor 1) acts via a dual mechanism:
- Directly activates β-globin gene transcription (prefers β over γ)
- Activates BCL11A expression → BCL11A then represses γ-globin
So KLF1 simultaneously turns β on and (via BCL11A) turns γ off. This dual action is so powerful that even partial KLF1 loss-of-function mutations in humans cause elevated HbF in adults.
4. The β-Globin Locus Control Region (LCR)
The β-globin gene cluster on chromosome 11 is controlled by a Locus Control Region (LCR) located ~50–100 kb upstream. The LCR acts as a master regulatory hub with hypersensitive sites (HS1–HS5) that physically loop to contact either the γ-globin or β-globin gene depending on developmental stage. Around birth, the LCR preferentially contacts β-globin, shifting transcriptional activity away from γ.
5. Additional Epigenetic Factors
| Factor | Role |
|---|---|
| MYB | Activates KLF1 expression; also has direct effects on HbF |
| SOX6 | Cooperates with BCL11A to silence γ-globin |
| NuRD complex | Chromatin remodeling that maintains γ-globin in a repressed state |
| TR2/TR4 (nuclear receptors) | Bind γ-globin promoter and recruit repressor complexes in adult cells |
| DNA methylation | The γ-globin promoter becomes increasingly methylated postnatally |
6. Why It Matters Clinically
The switch is not complete at birth — HbF levels fall gradually over 3–6 postnatal months. This is why:
- Sickle cell disease and β-thalassemia are asymptomatic in newborns (HbF is still protective)
- Symptoms emerge only as β-globin defects are "unmasked" after the switch completes
- HPFH (disruption of the perinatal switch) is clinically benign because persistent HbF compensates for absent HbA — and this is precisely the principle behind modern gene therapies
Summary in one sentence: The hemoglobin switch is primarily driven by the upregulation of BCL11A in bone marrow–derived erythroid progenitors, which — activated by KLF1 — silences γ-globin genes while β-globin is simultaneously activated, all coordinated by the LCR and a broader epigenetic reprogramming of the β-globin locus.
— Thompson & Thompson Genetics and Genomics in Medicine, 9th ed.; Molecular control of hemoglobin switching (EHA); KLF1 regulates BCL11A, Nature Genetics
This is a shared conversation. Sign in to Orris to start your own chat.